Rohit Nambisan, the CEO of Lokavant, spoke with Lori Ellis from BioSpace about the challenges in the U.S. healthcare market. He pointed out that the recent halt of digital health committees and the scaling back of diversity, equity, and inclusion (DEI) initiatives have left a gap in communication and clarity. Rohit emphasized the importance of maintaining best practices in clinical research to ensure treatments are safe and effective, especially for underserved patient communities.
- The suspension of advisory boards has created uncertainty, making it harder to move initiatives forward.
- DEI initiatives matter because they help ensure diverse patient groups are represented in clinical trials, which enhances scientific accuracy.
- It’s vital for the industry to uphold good science and ensure research reflects the populations that are most affected by specific diseases.
- Advocating for proper representation in clinical research isn’t just about diversity; it’s about the well-being of patients and ensuring their needs are met effectively.
In the end, standing up for good science means supporting diverse voices in research. This is not only right for patients, but it benefits the overall integrity of medical advancements.
